Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Phase 3

Active, not recruiting

• Conditions: Myelofibrosis (MF)
• Interventions: Drug: Navitoclax; Drug: Best Available Therapy (BAT); Drug: Ruxolitinib

• Registration Number: NCT04468984
• Lead Sponsor: AbbVie

Brief Summary

Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger. The purpose of this study is to assess safety and change in spleen volume when navitoclax is given in combination with ruxolitinib, compared to best available therapy, for adult participants with MF.

Navitoclax is an investigational drug (not yet approved) being developed for the treatment of MF. Participants in this study will be randomly selected (like picking numbers out of a hat) to be in 1 of 2 treatment arms. Neither participants nor the study doctor will be able to pick which treatment arm a participants enters. In Arm A, participants will receive navitoclax in combination with ruxolitinib. In Arm B, participants will receive the best available therapy (BAT) for MF. In Arm C, participants will receive navitoclax. Adult participants with a diagnosis of MF that came back or did not get better after earlier treatment will be enrolled. Approximately 330 participants will be enrolled in approximately 322 sites across the world.

In Arm A, participants will receive navitoclax tablet by mouth once daily with by mouth ruxolitinib tablet twice daily. In Arm B, participants will receive the BAT available to the investigator. In Arm C, participants will receive navitoclax tablet by mouth once daily. Participants will receive the study drug until they experience no benefit (determined by the investigator), participants cannot tolerate the study drugs, or participants withdraw consent. The approximate treatment duration is about 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of treatment will be checked by medical assessments, blood and bone marrow tests, checking for side effects, and completing questionnaires.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-10
• Study First Submitted QC: 2020-07-10
• Study First Posted: 2020-07-13
• Study Start: 2020-08-31
• Primary Completion: 2025-01-29
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-22
• Last Update Posted: 2025-04-24
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

• Must complete the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 on at least 4 out of the 7 days immediately prior to the date of randomization and must agree to collect MFSAF data daily by ePRO device during the study collection window.

  -- Has at least 2 symptoms each with an average score >= 3 or an average total score of >= 12, as measured by the MFSAF v4.0.

• Documented diagnosis of primary myelofibrosis (MF) as defined by the World Health Organization (WHO) classification, post polycythemia vera (PPV)-MF, or post essential thrombocytopenia (PET)-MF, characterized by bone marrow fibrosis grades 2 or 3.

• Classified as intermediate-2 or high-risk MF, as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+).

• Must currently be on treatment or have received prior treatment with a single Janus Kinase 2 (JAK2) inhibitor, ruxolitinib, and meet one of the following criteria (in addition to the minimum splenomegaly and symptom burden also required for eligibility):

  • Treatment with ruxolitinib for >= 24 weeks that was stopped due to lack of spleen response (refractory), or loss of spleen response or symptom control after a previous response (relapsed), or was continued despite relapsed/refractory status.

  • Treatment with ruxolitinib for < 24 weeks with documented disease progression while on therapy as defined by any of the following:

    • Appearance of new splenomegaly that is palpable to at least 5 cm below the left costal margin (LCM) in participants with no evidence of splenomegaly prior to the initiation of ruxolitinib.
    • A >= 100% increase in the palpable distance below the LCM in participants with measurable spleen distance 5 to 10 centimeters (cm) prior to the initiation of ruxolitinib.
    • A >= 50% increase in the palpable distance below the LCM in participants with measurable spleen distance > 10 cm prior to the initiation of ruxolitinib.
    • A spleen volume increase of >= 25% (as assessed by Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan) in participants with a spleen volume assessment prior to the initiation of ruxolitinib.

  • Prior treatment with ruxolitinib of at least 10 mg twice daily (BID) for >= 28 days with intolerance defined as new RBC transfusion requirement (at least 2 units/month for 2 months) while receiving a total daily ruxolitinib dose of >= 30 mg but unable to reduce dose further due to lack of efficacy.

Note: Participant must not require a ruxolitinib dose less than 10 mg BID (20 mg daily) due to prior history of ruxolitinibrelated ≥ Grade 3 toxicity.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• Splenomegaly defined as palpable spleen measurement >= 5 cm below left costal margin or spleen volume >= 450 cm3 as assessed centrally by MRI or CT scan.
• Baseline platelet count >= 100 × 10^9/L.

Exclusion Criteria

• Received prior treatment with a B-cell lymphoma 2 homology 3 (BH3)-mimetic compound, bromodomain and extra-terminal (BET) inhibitor, phosphoinositide 3- kinase and telomerase inhibitors (e.g., parsaclisib), prior use of > 1 JAK2 inhibitor or stem cell transplant.
• Eligible for stem cell transplantation at the time of study entry.
• Receiving medication that interferes with coagulation or platelet function within 3 days prior to the first dose of study drug or during the study treatment period except for low dose aspirin (up to 100 mg daily) and low molecular weight heparin (LMWH).
• Receiving anticancer therapy for an active malignancy or MF including chemotherapy, radiation therapy, hormonal therapy such that at least 5 half-lives of that medication is completed at least 7 days prior to the first dose of study drug or within 30 days prior to first dose of study drug, whichever is shorter, and during the study treatment period (other than any overlapping therapy as part of the selected BAT).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A: Navitoclax + Ruxolitinib	Navitoclax	Participants will receive navitoclax tablets once daily and ruxolitinib tablets twice daily.
Arm A: Navitoclax + Ruxolitinib	Ruxolitinib	Participants will receive navitoclax tablets once daily and ruxolitinib tablets twice daily.
Arm B: Best Available Therapy (BAT)	Best Available Therapy (BAT)	Participants will receive one of the BAT options, per the investigator's discretion.
Arm C: Continued Access for Navitoclax	Navitoclax	Participants will receive navitoclax tablets once daily.

Primary Outcome Measures

Name	Time	Method
Arms A and B: Percentage of Participants who achieve Spleen Volume Reduction of at least 35% at Week 24 (SVR35W24)	At Week 24	Reduction in spleen volume is measured by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT), per International Working Group (IWG) criteria.

Secondary Outcome Measures

Name	Time	Method
Arms A and B: Percentage of Participants who achieve at least 50% Reduction in Total Symptom Score (TSS)	Baseline (Week 0) Up to Week 24	Reduction in TSS is measured by Myelofibrosis Symptom Assessment Form (MFSAF) v4.0.
Arms A and B: Percentage of Participants who achieve Spleen Volume Reduction of at least 35% at any time	Baseline (Week 0) Up to Week 97	Reduction in spleen volume is measured by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT), per International Working Group (IWG) criteria.
Arms A and B: Percentage of Participants with Reduction in Grade of Bone Marrow Fibrosis	Baseline (Week 0) Up to Week 97	Reduction in grade of bone marrow fibrosis from baseline as measured by the European consensus grading system will be assessed.
Arms A and B: Percentage of Participants with Anemia Response	Baseline (Week 0) Up to Week 97	Anemia response per International Working Group (IWG) criteria will be assessed.
Arms A and B: Percentage of Participants with Overall Survival	Last Visit Up to 5 Years	Overall survival is defined as the time from start of study to the date of death from any cause.
Arms A and B: Percentage of Participants with Leukemia-free Survival	Last Visit Up to 5 Years	Leukemia free survival is the time from start of study to the date of development of leukemia.
Arms A and B: Percentage of Participants with Change in Fatigue	Baseline (Week 0) Up to Week 24	Change in fatigue will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 7a.
Arms A and B: Time to Deterioration of Physical Functioning	Baseline (Week 0) Up to Week 97	Time to deterioration of physical functioning is measured by the physical functioning domain of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30, or death.
Arms A and B: Percentage of Participants with at Least 50% Reduction in TSS	Baseline (Week 0) Up to Week 97	At least 50% reduction in TSS from baseline (at any time) as measured by MFSAF v4.0.

Trial Locations

Locations (229)

Medizinische Universitaet Graz /ID# 220919; 🇦🇹 Graz, Steiermark, Austria

Medizinische Universitaet Wien /ID# 220911; 🇦🇹 Vienna, Wien, Austria

Cliniques Universitaires UCL Saint-Luc /ID# 224221; 🇧🇪 Bruxelles, Bruxelles-Capitale, Belgium

Grand Hôpital De Charleroi - Notre Dame /ID# 224827; 🇧🇪 Charleroi, Hainaut, Belgium

UZ Gent /ID# 220841; 🇧🇪 Gent, Oost-Vlaanderen, Belgium

Vitaz /Id# 228150; 🇧🇪 Sint-Niklaas, Oost-Vlaanderen, Belgium

AZ-Delta /ID# 221469; 🇧🇪 Roeselare, West-Vlaanderen, Belgium

UMHAT Alexandrovska EAD /ID# 231652; 🇧🇬 Sofiya, Sofia, Bulgaria

UMHAT Dr Georgi Stranski EAD /ID# 231650; 🇧🇬 Pleven, Bulgaria

Acibadem City Clinic Tokuda University Hospital EAD /ID# 231649; 🇧🇬 Sofia, Bulgaria

University Health Network_Princess Margaret Cancer Centre /ID# 253942; 🇨🇦 Toronto, Ontario, Canada

CISSS-CA (Centre Integre de sante et de services sociaux de Chaudiere-Appalache) /ID# 222433; 🇨🇦 Levis, Quebec, Canada

McGill University Health Center Research Institute /ID# 222614; 🇨🇦 Montreal, Quebec, Canada

CHUQ- Hôpital de l'Enfant-Jesus /ID# 220888; 🇨🇦 Quebec City, Quebec, Canada

Clinical Hospital Dubrava /ID# 230801; 🇭🇷 Zagreb, Grad Zagreb, Croatia

Klinicka bolnica Merkur /ID# 230799; 🇭🇷 Zagreb, Grad Zagreb, Croatia

Klinicki bolnicki centar Zagreb /ID# 230798; 🇭🇷 Zagreb, Grad Zagreb, Croatia

Klinicki bolnicki centar Osijek /ID# 231503; 🇭🇷 Osijek, Osjecko-baranjska Zupanija, Croatia

Klinicki Bolnicki Centar (KBC) Split /ID# 230800; 🇭🇷 Split, Splitsko-dalmatinska Zupanija, Croatia

Fakultní Nemocnice Brno - Jihlavská /ID# 220959; 🇨🇿 Brno, Brno-mesto, Czechia

Vseobecna fakultni nemocnice v Praze /ID# 220969; 🇨🇿 Praha, Czechia

Aalborg University Hospital /ID# 224391; 🇩🇰 Aalborg, Nordjylland, Denmark

Roskilde Sygehus /ID# 224456; 🇩🇰 Roskilde, Sjælland, Denmark

Duplicate_CHU DE NICE-HOPITAL LARCHET II /ID# 256291; 🇫🇷 Nice, Alpes-Maritimes, France

CHU NIMES - Hopital Caremeau /ID# 219128; 🇫🇷 Nimes CEDEX 9, Gard, France

Centre Hospitalier Universitaire de Bordeaux /ID# 222696; 🇫🇷 Pessac CEDEX, Gironde, France

Hopital Avicenne - APHP /ID# 221287; 🇫🇷 Bobigny, Ile-de-France, France

CHU de Nantes, Hotel Dieu -HME /ID# 219127; 🇫🇷 Nantes, Pays-de-la-Loire, France

HCL - Hopital Lyon Sud /ID# 222695; 🇫🇷 Pierre Benite CEDEX, Rhone, France

Centre Hospitalier Métropole Savoie - Site Hôpital de Chambéry /ID# 223771; 🇫🇷 Chambery CEDEX, Savoie, France

Chu Angers /Id# 219129; 🇫🇷 Angers, France

Hôpital Saint-Louis /ID# 221390; 🇫🇷 Paris, France

Universitatsklinikum Mannheim /ID# 221529; 🇩🇪 Mannheim, Baden-Wuerttemberg, Germany

Stauferklinikum Schwaebisch Gmuend /ID# 223948; 🇩🇪 Mutlangen, Baden-Wuerttemberg, Germany

Gemeinschaftspraxis Dr. Heinrich und Prof. Bangerter /ID# 225025; 🇩🇪 Augsburg, Bayern, Germany

Universitaetsmedizin Rostock /ID# 224157; 🇩🇪 Rostock, Mecklenburg-Vorpommern, Germany

Augusta-Kranken-Anstalt gGmbH, Bochum-Mitte /ID# 224695; 🇩🇪 Bochum, Nordrhein-Westfalen, Germany

Klinikum Chemnitz gGmbH /ID# 224575; 🇩🇪 Chemnitz, Sachsen, Germany

BAG Freiberg-Richter, Jacobasch, Illmer, Wolf /ID# 221346; 🇩🇪 Dresden, Sachsen, Germany

OncoResearch Lerchenfeld GmbH /ID# 225034; 🇩🇪 Hamburg, Germany

Klinikum rechts der Isar /ID# 221526; 🇩🇪 Munich, Germany

Olympion General Clinic /ID# 261423; 🇬🇷 Patras, Achaia, Greece

General Hospital of Athens Laiko /ID# 221175; 🇬🇷 Athens, Attiki, Greece

General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 221179; 🇬🇷 Athens, Greece

University General Hospital of Patras /ID# 221178; 🇬🇷 RION Patras Achaia, Greece

General Hospital of Thessaloniki George Papanikolaou /ID# 221463; 🇬🇷 Thessaloniki, Greece

Fejér Vármegyei Szent György Egyetemi Oktató Kórház /ID# 220949; 🇭🇺 Szekesfehervar, Fejer, Hungary

Debreceni Egyetem-Klinikai Kozpont /ID# 220947; 🇭🇺 Debrecen, Hajdu-Bihar, Hungary

Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 220948; 🇭🇺 Kaposvár, Somogy, Hungary

Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz /ID# 220946; 🇭🇺 Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary

Szegedi Tudományegyetem /ID# 220955; 🇭🇺 Szeged, Hungary

HaEmek Medical Center /ID# 220839; 🇮🇱 Afula, H_efa, Israel

Rambam Health Care Campus /ID# 219121; 🇮🇱 Haifa, H_efa, Israel

The Lady Davis Carmel Medical Center /ID# 222973; 🇮🇱 Haifa, H_efa, Israel

Duplicate_Assuta Ashdod Medical Center /ID# 225281; 🇮🇱 Ashdod, HaDarom, Israel

Yitzhak Shamir Medical Center /ID# 222972; 🇮🇱 Zerifin, HaMerkaz, Israel

Galilee Medical Center /ID# 225280; 🇮🇱 Nahariya, HaTsafon, Israel

The Chaim Sheba Medical Center /ID# 219136; 🇮🇱 Ramat Gan, Tel-Aviv, Israel

Tel Aviv Sourasky Medical Center /ID# 219135; 🇮🇱 Tel Aviv, Tel-Aviv, Israel

Hadassah Medical Center-Hebrew University /ID# 219111; 🇮🇱 Jerusalem, Yerushalayim, Israel

Hadassah Mt. Scopus /ID# 253394; 🇮🇱 Jerusalem, Yerushalayim, Israel

Rabin Medical Center /ID# 219139; 🇮🇱 Petah Tikva, Israel

Duplicate_IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 221077; 🇮🇹 Bologna, Emilia-Romagna, Italy

Azienda Ospedaliero Universitaria Careggi /ID# 219090; 🇮🇹 Florence, Firenze, Italy

Duplicate_Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita /ID# 219087; 🇮🇹 Rome, Lazio, Italy

Fondazione IRCCS San Gerardo dei Tintori - Ospedale San Gerardo /ID# 225113; 🇮🇹 Monza, Monza E Brianza, Italy

Azienda Ospedaliera Universitaria Federico II /ID# 224673; 🇮🇹 Naples, Napoli, Italy

A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 221223; 🇮🇹 Torino, Piemonte, Italy

Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 225731; 🇮🇹 Rome, Roma, Italy

Azienda Ospedaliero Universitaria delle Marche /ID# 238438; 🇮🇹 Ancona, Italy

ASST Papa Giovanni XXIII /ID# 221222; 🇮🇹 Bergamo, Italy

AOU Policlinico G. Rodolico - San Marco /ID# 219089; 🇮🇹 Catania, Italy

Grande Ospedale Metropolitano Bianchi - Melacrino - Morelli P.O. Riuniti /ID# 221220; 🇮🇹 Reggio Calabria, Italy

Duplicate_University Hospital Santa Maria della Misericordia /ID# 221241; 🇮🇹 Udine, Italy

ASST Sette Laghi - Ospedale Di Circolo E Fondazione Macchi Varese /ID# 234183; 🇮🇹 Varese, Italy

Azienda ULSS 8 Berica /ID# 221079; 🇮🇹 Vicenza, Italy

Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital /ID# 221150; 🇯🇵 Nagoya-shi, Aichi, Japan

Fujita Health University Hospital /ID# 221598; 🇯🇵 Toyoake, Aichi, Japan

Hospital Universitario Virgen de las Nieves /ID# 253936; 🇪🇸 Granada, Spain

Hospital Universitario 12 de Octubre /ID# 233726; 🇪🇸 Madrid, Spain

Duplicate_Universitätsspital Basel /ID# 221261; 🇨🇭 Basel, Basel-Stadt, Switzerland

Inselspital, Universitaetsspital Bern /ID# 223439; 🇨🇭 Bern, Switzerland

Kaohsiung Chang Gung Memorial Hospital /ID# 218985; 🇨🇳 Kaohsiung City, Kaohsiung, Taiwan

Chi Mei Hospital - Liouying /ID# 221144; 🇨🇳 Tainan City, Tainan, Taiwan

National Taiwan University Hospital /ID# 271207; 🇨🇳 Taipei City, Taipei, Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 218980; 🇨🇳 Kaohsiung, Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 271389; 🇨🇳 Kaohsiung, Taiwan

China Medical University Hospital /ID# 218979; 🇨🇳 Taichung, Taiwan

National Cheng Kung University Hospital /ID# 271206; 🇨🇳 Tainan, Taiwan

Taipei Veterans General Hosp /ID# 221147; 🇨🇳 Taipei, Taiwan

Linkou Chang Gung Memorial Hospital /ID# 218982; 🇨🇳 Taoyuan City, Taiwan

Medipol Mega Üniversite Hastanesi /ID# 271374; 🇹🇷 Tuzla, Istanbul, Turkey

Gulhane Askeri Tip Academy /ID# 224568; 🇹🇷 Ankara, Turkey

Hacettepe Universitesi Hastaneleri /ID# 271084; 🇹🇷 Ankara, Turkey

Trakya University Medical Facu /ID# 224572; 🇹🇷 Edirne, Istanbul, Turkey

Ege University Medical Faculty /ID# 224570; 🇹🇷 Izmir, Turkey

Mersin University Medical /ID# 224571; 🇹🇷 Mersin, Turkey

Ondokuz mayis University Facul /ID# 224567; 🇹🇷 Samsun, Turkey

Feofaniya Clinical Hospital of State Management of Affairs /ID# 271397; 🇺🇦 Kyiv, Ukraine

Guys and St Thomas NHS Foundation Trust /ID# 221041; 🇬🇧 London, Greater London, United Kingdom

United Lincolnshire Hospitals NHS Trust /ID# 224613; 🇬🇧 Lincoln, Lincolnshire, United Kingdom

James Paget University Hospitals NHS Foundation Trust /ID# 221219; 🇬🇧 Great Yarmouth, Norfolk, United Kingdom

University Hospitals Birmingham NHS Foundation Trust /ID# 221334; 🇬🇧 Birmingham, United Kingdom

NHS Lothian /ID# 224378; 🇬🇧 Edinburgh, United Kingdom

The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 221335; 🇬🇧 Newcastle upon Tyne, United Kingdom

Hanusch Krankenhaus /ID# 220912; 🇦🇹 Wien, Austria

ZAS Cadix /ID# 221468; 🇧🇪 Antwerp, Antwerpen, Belgium

UMHAT Sveti Ivan Rilski /ID# 231651; 🇧🇬 Sofia, Bulgaria

UMHAT Sveta Marina /ID# 234119; 🇧🇬 Varna, Bulgaria

Juravinski Cancer Centre /ID# 220887; 🇨🇦 Hamilton, Ontario, Canada

Ottawa Hospital Research Institute /ID# 238858; 🇨🇦 Ottawa, Ontario, Canada

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 221078; 🇮🇹 Palermo, Italy

Ehime University Hospital /ID# 221158; 🇯🇵 Toon-shi, Ehime, Japan

Kyushu University Hospital /ID# 221606; 🇯🇵 Fukuoka-shi, Fukuoka, Japan

Fukushima Medical University Hospital /ID# 221877; 🇯🇵 Fukushima-shi, Fukushima, Japan

Gifu University Hospital /ID# 224371; 🇯🇵 Gifu-shi, Gifu, Japan

Sapporo Hokuyu Hospital /ID# 221149; 🇯🇵 Sapporo-shi, Hokkaido, Japan

Kobe City Medical Center General Hospital /ID# 221156; 🇯🇵 Kobe-shi, Hyogo, Japan

Kanazawa University Hospital /ID# 223028; 🇯🇵 Kanazawa-shi, Ishikawa, Japan

Iwate Medical University Hospital /ID# 222044; 🇯🇵 Shiwa-gun, Iwate, Japan

Hospital Regional Universitario de Malaga /ID# 221906; 🇪🇸 Malaga, Spain

Hospital Universitario de Salamanca /ID# 221904; 🇪🇸 Salamanca, Spain

Hospital Universitario Virgen del Rocio /ID# 221932; 🇪🇸 Sevilla, Spain

Hospital Clinico Universitario de Valencia /ID# 220920; 🇪🇸 Valencia, Spain

Skane University Hospital Lund /ID# 220834; 🇸🇪 Lund, Skane Lan, Sweden

Hospital Parc de Salut del Mar /ID# 220922; 🇪🇸 Barcelona, Spain

Hospital Universitario Vall d'Hebron /ID# 240979; 🇪🇸 Barcelona, Spain

Hospital Universitario La Paz /ID# 224813; 🇪🇸 Madrid, Spain

Ironwood Cancer & Res Ctr /ID# 222162; 🇺🇸 Chandler, Arizona, United States

Highlands Oncology Group, PA /ID# 221826; 🇺🇸 Springdale, Arkansas, United States

City of Hope /ID# 218996; 🇺🇸 Duarte, California, United States

Providence - St. Jude Medical Center /ID# 271382; 🇺🇸 Fullerton, California, United States

Moores Cancer Center /ID# 271596; 🇺🇸 La Jolla, California, United States

Moores Cancer Center at UC San Diego /ID# 219009; 🇺🇸 La Jolla, California, United States

Long Beach Memorial Medical Ct /ID# 224542; 🇺🇸 Long Beach, California, United States

Icri /Id# 221967; 🇺🇸 Whittier, California, United States

St. Mary's Hospital Regional Cancer Center /ID# 224229; 🇺🇸 Grand Junction, Colorado, United States

Augusta University Georgia Cancer Center /ID# 219051; 🇺🇸 Augusta, Georgia, United States

Columbus Regional Research Institute /ID# 224410; 🇺🇸 Columbus, Georgia, United States

University of Chicago Medical Center /ID# 271373; 🇺🇸 Chicago, Illinois, United States

Northwest Oncology & Hematology - Elk Grove Village /ID# 222818; 🇺🇸 Elk Grove Village, Illinois, United States

Loyola University Medical Ctr /ID# 219048; 🇺🇸 Maywood, Illinois, United States

Indiana Blood & Marrow Transpl /ID# 221587; 🇺🇸 Indianapolis, Indiana, United States

Tulane Medical Center - New Orleans /ID# 222940; 🇺🇸 New Orleans, Louisiana, United States

Duplicate_Ochsner Clinic Foundation-New Orleans /ID# 222777; 🇺🇸 New Orleans, Louisiana, United States

American Oncology Partners of Maryland /ID# 222836; 🇺🇸 Bethesda, Maryland, United States

Dana-Farber Cancer Institute /ID# 218998; 🇺🇸 Boston, Massachusetts, United States

University of Michigan /ID# 218463; 🇺🇸 Ann Arbor, Michigan, United States

Henry Ford Hospital /ID# 221190; 🇺🇸 Detroit, Michigan, United States

William Beaumont Hospital /ID# 222705; 🇺🇸 Royal Oak, Michigan, United States

Saint Louis University Cancer Center /ID# 222287; 🇺🇸 Saint Louis, Missouri, United States

Summit Medical Group-Florham Park /ID# 222620; 🇺🇸 Florham Park, New Jersey, United States

Hackensack Univ Med Ctr /ID# 219047; 🇺🇸 Hackensack, New Jersey, United States

The Cancer Institute at St. Francis Hospital /ID# 231782; 🇺🇸 Greenvale, New York, United States

Manhattan Hematology Oncology MHO Associates /ID# 223193; 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 221081; 🇺🇸 New York, New York, United States

Atrium Health Wake Forest Baptist Medical Center /ID# 222899; 🇺🇸 Winston-Salem, North Carolina, United States

MetroHealth Medical Center /ID# 222650; 🇺🇸 Cleveland, Ohio, United States

Pennsylvania Cancer Specialists & Research Institute /ID# 271376; 🇺🇸 Gettysburg, Pennsylvania, United States

Hospital of the University of Pennsylvania /ID# 219001; 🇺🇸 Philadelphia, Pennsylvania, United States

Fox Chase Cancer Center /ID# 223955; 🇺🇸 Philadelphia, Pennsylvania, United States

Texas Oncology - Abilene - Antilley Road /ID# 271379; 🇺🇸 Abilene, Texas, United States

Duplicate_Houston Methodist Hospital /ID# 223103; 🇺🇸 Houston, Texas, United States

University of Texas Health San Antonio MD Anderson Cancer Center /ID# 233942; 🇺🇸 San Antonio, Texas, United States

Utah Cancer Specialists Salt Lake Clinic /ID# 221962; 🇺🇸 Salt Lake City, Utah, United States

Virginia Cancer Specialists - Fairfax /ID# 223016; 🇺🇸 Fairfax, Virginia, United States

Providence Everett /ID# 223130; 🇺🇸 Everett, Washington, United States

Yakima Valley Memorial Hosp /ID# 224368; 🇺🇸 Yakima, Washington, United States

HSHS St. Vincent Hospital /ID# 224468; 🇺🇸 Green Bay, Wisconsin, United States

The Kinghorn Cancer Centre /ID# 221097; 🇦🇺 Darlinghurst, New South Wales, Australia

Border Medical Oncology Research Unit Albury Wodonga Regiona /ID# 223848; 🇦🇺 East Albury, New South Wales, Australia

Calvary Mater Newcastle /ID# 224324; 🇦🇺 Waratah, New South Wales, Australia

The Alfred Hospital /ID# 221096; 🇦🇺 Melbourne, Victoria, Australia

Royal Perth Hospital /ID# 221099; 🇦🇺 Perth, Western Australia, Australia

Universitaetsklinikum St. Poelten /ID# 221709; 🇦🇹 Sankt Poelten, Niederoesterreich, Austria

Ordensklinikum Linz GmbH Elisabethinen /ID# 220914; 🇦🇹 Linz, Oberoesterreich, Austria

Klinikum Wels-Grieskirchen GmbH /ID# 220915; 🇦🇹 Wels, Oberoesterreich, Austria

Aomori Prefectural Central Hospital /ID# 221778; 🇯🇵 Aomori-shi, Aomori, Japan

Chiba University Hospital /ID# 224546; 🇯🇵 Chiba-shi, Chiba, Japan

National Cancer Center Hospital East /ID# 226653; 🇯🇵 Kashiwa-shi, Chiba, Japan

Shonan Kamakura General Hospital /ID# 223030; 🇯🇵 Kamakura-shi, Kanagawa, Japan

Kumamoto Shinto General Hospital /ID# 255645; 🇯🇵 Kumamoto-shi, Kumamoto, Japan

Kyoto University Hospital /ID# 223008; 🇯🇵 Kyoto-shi, Kyoto, Japan

Mie University Hospital /ID# 221665; 🇯🇵 Tsu-shi, Mie, Japan

University of Miyazaki Hospital /ID# 221821; 🇯🇵 Miyazaki-shi, Miyazaki, Japan

Niigata University Medical & Dental Hospital /ID# 223034; 🇯🇵 Niigata-shi, Niigata, Japan

Kurashiki Central Hospital /ID# 221690; 🇯🇵 Kurashiki-shi, Okayama, Japan

Kansai Medical University Hospital /ID# 257289; 🇯🇵 Hirakata-shi, Osaka, Japan

The University of Osaka Hospital /ID# 221159; 🇯🇵 Suita-shi, Osaka, Japan

Dokkyo Medical University Saitama Medical Center /ID# 222334; 🇯🇵 Koshigaya, Saitama, Japan

Juntendo University Shizuoka Hospital /ID# 221780; 🇯🇵 Izunokuni-shi, Shizuoka, Japan

Juntendo University Hospital /ID# 221154; 🇯🇵 Bunkyo-ku, Tokyo, Japan

Nippon Medical School Hospital /ID# 221676; 🇯🇵 Bunkyo-ku, Tokyo, Japan

Tokyo Medical University Hospital /ID# 221540; 🇯🇵 Shinjuku-ku, Tokyo, Japan

Tokyo Metropolitan Bokutoh Hospital /ID# 254774; 🇯🇵 Sumida-ku, Tokyo, Japan

University of Yamanashi Hospital /ID# 221706; 🇯🇵 Chuo-shi, Yamanashi, Japan

IMSUT Hospital, The Institute of Medical Science, The University of Tokyo /ID# 257944; 🇯🇵 Tokyo, Japan

Pusan National University Hospital /ID# 220980; 🇰🇷 Busan, Busan Gwang Yeogsi, Korea, Republic of

Gachon University Gil Medical Center /ID# 220972; 🇰🇷 Incheon, Gyeonggido, Korea, Republic of

Seoul National University Hospital /ID# 219060; 🇰🇷 Seoul, Seoul Teugbyeolsi, Korea, Republic of

Samsung Medical Center /ID# 221091; 🇰🇷 Seoul, Seoul Teugbyeolsi, Korea, Republic of

The Catholic University of Korea, Seoul St. Marys Hospital /ID# 219061; 🇰🇷 Seoul, Seoul Teugbyeolsi, Korea, Republic of

Aotearoa Clinical Trials /ID# 232201; 🇳🇿 Papatoetoe, Auckland, New Zealand

Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopern /ID# 221161; 🇵🇱 Lodz, Lodzkie, Poland

Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie /ID# 221124; 🇵🇱 Lublin, Lubelskie, Poland

SP ZOZ Szpital Uniwersytecki w Krakowie /ID# 221160; 🇵🇱 Krakow, Malopolskie, Poland

Lux Med Onkologia - Szpital Szamocka /Id# 221265; 🇵🇱 Warszawa, Mazowieckie, Poland

MTZ Clinical Research Powered by Pratia /ID# 221759; 🇵🇱 Warszawa, Mazowieckie, Poland

Uniwersyteckie Centrum Kliniczne /ID# 221298; 🇵🇱 Gdansk, Pomorskie, Poland

ARS-MEDICAL Sp. z o.o. /ID# 238336; 🇵🇱 Pila, Wielkopolskie, Poland

Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Medycznego im. Karola /ID# 241031; 🇵🇱 Poznan, Wielkopolskie, Poland

Pratia Onkologia Katowice /ID# 224526; 🇵🇱 Katowice, Poland

Hospital del Centro Comprensivo de Cancer de la UPR /ID# 223281; 🇵🇷 San Juan, Puerto Rico

Moscow State budget healthcare /ID# 221116; 🇷🇺 Moscow, Moskva, Russian Federation

Clinic UZI 4D /ID# 221303; 🇷🇺 Pyatigorsk, Stavropol Skiy Kray, Russian Federation

Hospital n.a. V.V. Veresaev /ID# 225221; 🇷🇺 Moscow, Russian Federation

Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 221115; 🇷🇺 Sankt-Peterburg, Russian Federation

Almazov National Medical Research Centre /ID# 221114; 🇷🇺 Sankt-Peterburg, Russian Federation

Tula Regional Clinical Hospital /ID# 221302; 🇷🇺 Tula, Russian Federation

University Clinical Center Serbia /ID# 231058; 🇷🇸 Belgrade, Beograd, Serbia

Clin Hosp Ctr Bezanijska Kosa /ID# 231059; 🇷🇸 Belgrade, Beograd, Serbia

University Clinical Center Vojvodina /ID# 231057; 🇷🇸 Novi Sad, Serbia

Duplicate_Wits Clinical Research Site /ID# 231554; 🇿🇦 Johannesburg, Gauteng, South Africa

Alberts Cellular Therapy /ID# 231556; 🇿🇦 Pretoria, Gauteng, South Africa

Complejo Hospitalario Universitario A Coruña /ID# 224617; 🇪🇸 A Coruña, A Coruna, Spain

Duplicate_Hospital Clínico Universitario de Santiago-CHUS /ID# 221616; 🇪🇸 Santiago de Compostela, A Coruna, Spain

Hospital Universitario Central de Asturias /ID# 224815; 🇪🇸 Oviedo, Asturias, Spain

Hospital Universitario Germans Trias i Pujol /ID# 233727; 🇪🇸 Badalona, Barcelona, Spain

Hospital Universitario Dr. Negrin /ID# 220923; 🇪🇸 Las Palmas de Gran Canaria, Las Palmas, Spain